+ Watch CAMH
on My Watchlist
The Company is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease.
This technology will become the standard for determining whether defibs are needed or not. Major clinical trials all support this. Another larege clinical trial is due in Nov, 2007. Insurance coverage already in place and more to come. Recent marketing colaboration with STJ is going to propel sales and adoption. NASDAQ listing will also add to PPS appreciation. CAMH will explode over the 2 years.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions